Ferrara A. Increasing prevalence of gestational diabetes mellitus: a public health perspective. Diabetes Care. 2007;30(2):S141-146.
Zhu Y, Zhang C. Prevalence of gestational diabetes and risk of progression to type 2 diabetes: a global perspective. Curr Diab Rep. 2016;16:7.
Article PubMed PubMed Central Google Scholar
Plows JF, Stanley JL, Baker PN, Reynolds CM, Vickers MH. The Pathophysiology of gestational diabetes mellitus. Int J Mol Sci. 2018;19:3342.
Article PubMed Central Google Scholar
Barbour LA, McCurdy CE, Hernandez TL, Kirwan JP, Catalano PM, Friedman JE. Cellular mechanisms for insulin resistance in normal pregnancy and gestational diabetes. Diabetes Care. 2007;30(2):S112-119.
Article CAS PubMed Google Scholar
Fetita L-S, Sobngwi E, Serradas P, Calvo F, Gautier J-F. Consequences of fetal exposure to maternal diabetes in offspring. J Clin Endocrinol Metab. 2006;91:3718–24.
Article CAS PubMed Google Scholar
Langer O, Yogev Y, Most O, Xenakis EMJ. Gestational diabetes: the consequences of not treating. Am J Obstet Gynecol. 2005;192:989–97.
Mistry SK, Das Gupta R, Alam S, Kaur K, Shamim AA, Puthussery S. Gestational diabetes mellitus (GDM) and adverse pregnancy outcome in South Asia: a systematic review. Endocrinol Diabetes Metab. 2021;4: e00285.
Article PubMed PubMed Central Google Scholar
Wendland EM, Torloni MR, Falavigna M, Trujillo J, Dode MA, Campos MA, et al. Gestational diabetes and pregnancy outcomes–a systematic review of the world health organization (WHO) and the international association of diabetes in pregnancy study groups (IADPSG) diagnostic criteria. BMC Pregnancy Childbirth. 2012;12:23.
Article PubMed PubMed Central Google Scholar
Vohr BR, Boney CM. Gestational diabetes: the forerunner for the development of maternal and childhood obesity and metabolic syndrome? J Matern Fetal Neonatal Med. 2008;21:149–57.
Article CAS PubMed Google Scholar
Petitt DJ, Bennett PH, Knowler WC, Baird HR, Aleck KA. Gestational diabetes mellitus and impaired glucose tolerance during pregnancy. Long-term effects on obesity and glucose tolerance in the offspring. Diabetes. 1985;34(2):119–22.
Hartling L, Dryden DM, Guthrie A, Muise M, Vandermeer B, Donovan L. Benefits and harms of treating gestational diabetes mellitus: a systematic review and meta-analysis for the U.S. preventive services task force and the national institutes of health office of medical applications of research. Ann Intern Med. 2013;159:123–9.
American Diabetes Association. 13. management of diabetes in pregnancy: standards of medical care in diabetes-2018. Diabetes Care. 2018;41:S137-43.
Association AD. 8 Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2018. Diabetes Care Am Diabet Assoc. 2018;41:S73-85.
Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000;49:2142–8.
Article CAS PubMed Google Scholar
Gough SCL. A review of human and analogue insulin trials. Diabetes Res Clin Pract. 2007;77:1–15.
Article CAS PubMed Google Scholar
Yki-Järvinen H, Dressler A, Ziemen M, HOE 901/300s Study Group. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 study group. Diabetes Care. 2000;23:1130–6.
Frier BM, Russell-Jones D, Heise T. A comparison of insulin detemir and neutral protamine Hagedorn (isophane) insulin in the treatment of diabetes: a systematic review. Diabetes Obes Metab. 2013;15:978–86.
Article CAS PubMed Google Scholar
Lepercq J, Lin J, Hall GC, Wang E, Dain M-P, Riddle MC, et al. Meta-analysis of maternal and neonatal outcomes associated with the use of insulin glargine versus NPH insulin during pregnancy. Obstet Gynecol Int. 2012;2012: 649070.
Article PubMed PubMed Central Google Scholar
Pollex E, Moretti ME, Koren G, Feig DS. Safety of insulin glargine use in pregnancy: a systematic review and meta-analysis. Ann Pharmacother. 2011;45:9–16.
Article CAS PubMed Google Scholar
Lv S, Wang J, Xu Y. Safety of insulin analogs during pregnancy: a meta-analysis. Arch Gynecol Obstet. 2015;292:749–56.
Article CAS PubMed Google Scholar
PRISMA. http://www.prisma-statement.org/PRISMAStatement/. Accessed on Sep 11 2021.
Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. British Medical Journal Publishing Group; 2019; 366:l4898. https://www.bmj.com/content/366/bmj.l4898. Accessed on Sep 3 2022.
Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. Research Synthesis Methods. 2021 12:55–61. Available from: https://onlinelibrary.wiley.com/doi/abs/https://doi.org/10.1002/jrsm.1411. Accessed on Sep 3 2022.
Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. https://handbook-5-1.cochrane.org/. Accessed on 22 Aug 2021
Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ [Internet]. British Medical Journal Publishing Group; 1997. 315:629–34. https://www.bmj.com/content/315/7109/629. Accessed on 16 Aug 2021.
McMaster University > CE&B Grade > GRADEpro. https://cebgrade.mcmaster.ca/gradepro.html. Accessed on 3 Sep 2022.
FishelBartal M, Ward C, Blackwell SC, Ashby Cornthwaite JA, Zhang C, Refuerzo JS, et al. Detemir vs neutral protamine Hagedorn insulin for diabetes mellitus in pregnancy: a comparative effectiveness, randomized controlled trial. Am J Obstet Gynecol. 2021;225:87.e1-87.e10.
Chico A, Herranz L, Corcoy R, Ramírez O, Goya MM, Bellart J, et al. Glycemic control and maternal and fetal outcomes in pregnant women with type 1 diabetes according to the type of basal insulin. Eur J Obstet Gynecol Reprod Biol. 2016;206:84–91.
Article CAS PubMed Google Scholar
FishelBartal M, Ward C, Refuerzo JS, Ashimi SS, Joycelyn CA, Chen H-Y, et al. Basal insulin analogs versus neutral protamine Hagedorn for type 2 diabetics. Am J Perinatol. 2020;37:30–6.
Herrera KM, Rosenn BM, Foroutan J, Bimson BE, Al Ibraheemi Z, Moshier EL, et al. Randomized controlled trial of insulin detemir versus NPH for the treatment of pregnant women with diabetes. Am J Obstet Gynecol. 2015;213(426):e1-7.
Hod M, Mathiesen ER, Jovanovič L, McCance DR, Ivanisevic M, Durán-Garcia S, et al. A randomized trial comparing perinatal outcomes using insulin detemir or neutral protamine Hagedorn in type 1 diabetes. J Matern Fetal Neonatal Med. 2014;27:7–13.
Article CAS PubMed Google Scholar
ji J, He Z, Yang Z, Mi Y, Guo N, Zhao H, et al. Comparing the efficacy and safety of insulin detemir versus neutral protamine Hagedorn insulin in treatment of diabetes during pregnancy: a randomized, controlled study. BMJ Open Diabetes Res Care. 2020;8:e001155.
Article PubMed PubMed Central Google Scholar
Mathiesen ER, Hod M, Ivanisevic M, Duran Garcia S, Brøndsted L, Jovanovic L, et al. Maternal efficacy and safety outcomes in a randomized, controlled trial comparing insulin detemir with NPH insulin in 310 pregnant women with type 1 diabetes. Diabetes Care. 2012;35:2012–7.
Article CAS PubMed PubMed Central Google Scholar
Sleeman A, Odom J, Schellinger M. Comparison of hypoglycemia and safety outcomes with long-acting insulins versus insulin NPH in pregestational and gestational diabetes. Ann Pharmacother. 2020;54:669–75.
Di Cianni G, Torlone E, Lencioni C, Bonomo M, Di Benedetto A, Napoli A, et al. Perinatal outcomes associated with the use of glargine during pregnancy. Diabet Med. 2008;25:993–6.
Article PubMed PubMed Central Google Scholar
Egerman RS, Ramsey RD, Kao LW, Bringman JJ, Haerian H, Kao JL, et al. Perinatal outcomes in pregnancies managed with antenatal insulin glargine. Am J Perinatol. 2009;26:591–5.
Fang YMV, MacKeen D, Egan JFX, Zelop CM. Insulin glargine compared with neutral protamine Hagedorn insulin in the treatment of pregnant diabetics. J Matern Fetal Neonatal Med. 2009;22:249–53.
Article CAS PubMed Google Scholar
Imbergamo MP, Amato MC, Sciortino G, Gambina M, Accidenti M, Criscimanna A, et al. Use of glargine in pregnant women with type 1 diabetes mellitus: a case-control study. Clin Ther. 2008;30:1476–84.
Article CAS PubMed Google Scholar
Negrato CA, Rafacho A, Negrato G, Teixeira MF, Araújo CAR, Vieira L, et al. Glargine vs. NPH insulin therapy in pregnancies complicated by diabetes: an observational cohort study. Diabetes Res Clin Pract. 2010;89:46–51.
Article CAS PubMed Google Scholar
Pöyhönen-Alho M, Rönnemaa T, Saltevo J, Ekblad U, Kaaja RJ. Use of insulin glargine during pregnancy. Acta Obstet Gynecol Scand. 2007;86:1171–4.
Price N, Bartlett C, Gillmer M. Use of insulin glargine during pregnancy: a case-control pilot study. BJOG. 2007;114:453–7.
Article CAS PubMed Google Scholar
Smith JG, Manuck TA, White J, Merrill DC. Insulin glargine versus neutral protamine Hagedorn insulin for treatment of diabetes in pregnancy. Am J Perinatol. 2009;26:57–62.
留言 (0)